Avtor/Urednik		Srikanthan, Amirrtha; Ethier, Josee-Lyne; Ocaña, Alberto; Šeruga, Boštjan; Krzyzanowska, Monika K.; Amir, Eitan
Naslov		Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors
Tip		članek
Vol. in št.		Letnik 10, št. 3
Leto izdaje		2015
ISSN		1932-6203 - PloS one
Jezik		eng
Abstrakt		Treatment with small molecule tyrosine kinase inhibitors (TKIs) has improved survival in many cancers, yet has been associated with an increased risk of adverse events. Warnings of cardiovascular events are common in drug labels of many TKIs. Despite these warnings, cardiovascular toxicity of patients treated with TKIs remains unclear. Here, we evaluate the cardiovascular outcomes of advanced cancer patients treated with small molecule tyrosine kinase inhibitors. Methods A population based cohort study was undertaken involving adults aged >18 years in Ontario, Canada, diagnosed with any advanced malignancy between 2006 and 2012. Data were extracted from linked administrative governmental databases. Adults with advanced cancer receiving TKIs were identified and followed throughout the time period. The main outcomes of interest were rates of hospitalization for ischemic heart disease (acute myocardial infarction and angina) or cerebrovascular accidents and death. Results 1642 patients with a mean age of 62.5 years were studied; 1046 were treated with erlotinib, 166 with sorafenib and 430 with sunitinib. Over the 380 day median follow-up period (range 6-1970 days), 1.1% of all patients had ischemic heart events, 0.7% had cerebrovascular accidents and 72.1% died. Rates of cardiovascular events were similar to age and gender-matched individuals without cancer. In a subgroup analysis of treatment patients with a prior history of ischemic heart disease, 3.3% had ischemic heart events while 1.2% had cerebrovascular accidents. Conclusions TKIs do not appear to increase the cause-specific hazard of ischemic heart disease and cerebrovascular accidents compared to age and gender-matched individuals without advanced cancer.
Proste vsebinske oznake		kardiovaskularna toksičnost trdni tumorji zdravljenje inhibitorji tirozin kinaze cardiovascular toxicity solid tumors treatment multi-tyrosin kinase inhibitors